Alpine Immune Sciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALPN Nasdaq 8731 https://www.alpineimmunesciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpine Immune Sciences Inc

Are Options Traders Betting on a Big Move in Alpine (ALPN) Stock? - Jan 17th, 2023 1:36 pm
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference - Nov 22nd, 2022 9:15 pm
Alpine Immune Sciences Third Quarter 2022 Earnings: Misses Expectations - Nov 16th, 2022 10:58 am
Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates - Nov 14th, 2022 10:25 pm
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov 14th, 2022 9:05 pm
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results - Nov 7th, 2022 9:30 pm
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength? - Nov 4th, 2022 8:46 am
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting - Nov 3rd, 2022 8:15 pm
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition - Nov 3rd, 2022 1:00 pm
Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Nov 2nd, 2022 2:01 pm
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences - Oct 26th, 2022 8:30 pm
Alpine Immune Sciences halts cancer drug trials after 2nd patient death - Oct 25th, 2022 5:04 am
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death - Oct 24th, 2022 2:33 pm
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2) - Oct 24th, 2022 11:30 am
Investors in Alpine Immune Sciences (NASDAQ:ALPN) have made a splendid return of 159% over the past three years - Oct 18th, 2022 12:01 pm
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last? - Oct 12th, 2022 12:22 pm
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors - Sep 26th, 2022 12:00 pm
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering - Sep 21st, 2022 3:26 am
Alpine Immune Sciences Announces Proposed Public Offering - Sep 20th, 2022 8:15 pm
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day - Sep 12th, 2022 8:05 pm